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Abstract
Background: The objective of the study was to determine the genetic basis of Major Depressive
Disorder, and the capacity to respond to antidepressant treatment. An association study of 21
candidate polymorphisms relevant to monoamine function and the mechanism of antidepressant
response was conducted in 3 phenotypically distinct samples: a group with chronic or recurrent
depression unable to respond to antidepressants (non-responders) (n = 58), a group capable of
symptomatic improvement with or without treatment (responders) (n = 39), and volunteer
controls (n = 85). The responders and non-responders constituted a larger group of depressed
subjects.
Methods:  A candidate gene approach was employed to asses the genetics basis of Major
Depressive Disorder. The genotypic frequencies of selected polymorphisms were compared
between the controls and depressed subjects. To asses the genetics basis of the capacity to respond
to antidepressant treatment, the responders were compared to the non-responders. Candidate
genes were chosen based on functional studies and proximity to whole genome linkage findings in
the literature. Risk genotypes were identified by previous functional studies and association studies.
Results: A statistically significant difference in genotype frequency for the SLC6A4 intron 2 VNTR
was detected between the subjects with a history of depression and controls (p = 0.004).
Surprisingly, a statistically significant difference was detected between responders and non-
responders for the DRD4  exon III VNTR genotype frequencies (p = 0.009). Furthermore, a
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difference between the controls and depressed subjects as well as between the controls and non-
responders was detected for the number and distribution of risk genotypes in each group.
Conclusion: An association between several monoamine-related genes and Major Depressive
Disorder is supported. The data suggest that the two depressive phenotypes are genetically
different, inferring that the genetic basis for the capacity to respond to standard antidepressant
treatment, and the genetic susceptibility to Major Depressive Disorder may be independent. In
addition, a proof of concept is provided demonstrating that the number of risk genotypes may be
an indication of susceptibility of major depressive disorder and the severity of the disorder.
Background
Depression affects more than 40 million Americans at
some time during their lives and represents one of the
most debilitating medical conditions. A substantial body
of evidence drawn from a range of methods, proband
groups, and diagnostic criteria has established that a
familial phenotype is present in patients with major
depression [1-7]. Despite their limitations, molecular
methods such as candidate gene association studies also
support the concept of a genetic influence in vulnerability
to depression [8,9]. Although genetic studies promise to
improve our understanding of the pathophysiological
and genetic aspects of the depressive syndrome, such
understanding is limited by the genetic complexity and
lack of discrete, etio-pathologically related, and homoge-
neous "depression" phenotypes.
Treatment resistant depression (TRD) is a characteristic of
some depression phenotypes. It can range from not being
able to respond to one medication, to not clinically
responding to electroconvulsive therapy[10]. TRD, or
non-response can be viewed as a spectrum of severity of
major depressive disorder, as the amount of suffering is
greater for those with TRD, than those without[11].
Whether or not TRD is a subtype of depression with a dis-
tinct underlying biology is still unknown and under inves-
tigation. It is possible that to some extent TRD is a result
of hyperfunctioning enzymes that metabolize typical anti-
depressant medications [12]. In this case, the TRD sub-
jects would have a genetic background that leads to a
pharmacokinetic difference from the depressive group
which is capable of antidepressant treatment response.
This genetic discrepancy between two diagnostically simi-
lar groups (though phenotypically difference in terms of
response profiles) may be detectable, and would provide
insight to the biology of treatment resistant depression.
To explore genetic differences within depression endo-
phenotypes, we genotyped Caucasian subjects with uni-
polar major depression from two distinct treatment
response profiles: those able to respond to treatment, and
those not able to respond. The genes being studied encode
for receptors, transporters, synthetic or degradation
enzymes, transcription factors, and neurotrophic factors
related to monoamine function. We hypothesized that the
depressive group as a whole would be genetically distinct
from the healthy controls. It was predicted that there
would be a higher frequency of "risk" genotypes (exces-
sive or deficient in functioning depending on the case) in
the depressive groups when compared to the controls.
We report one two single gene findings and one polygenic
discovery. A difference in genotypic frequency between
the controls and depressed subjects was detected in the
serotonin transporter intron 2 VNTR polymorphism. A
surprising difference was detected between the responder
and non-responders in the dopamine D4 receptor exon III
VNTR. Furthermore, we demonstrate that depressed sub-
jects have more risk genotypes that non-depressed sub-
jects, and that non-responders have the most risk
genotypes of all our phenotypic groups analyzed.
Methods
Subjects
Ninety-seven subjects, aged 18 to 85 years and diagnosed
with unipolar major depression (DSM-IV)[13] partici-
pated in the study (see Table 1). Fifty-eight of these sub-
jects had participated in a research trial for treatment
resistant depression (TRD); selection criteria for this
group included clinical diagnosis of chronic or recurrent
depression and failure to achieve remission after at least
two adequate antidepressant trials as documented by the
Antidepressant Treatment History Form (ATHF) [14-20]
These subjects are a subgroup of a vagal nerve stimulation
(VNS) trial, and express a highly debilitating course of
major depressive disorder, and nearly 90% failed to
respond to selective serotonin re-uptake inhibitors
(SSRIs). Further details about the subjects has been previ-
ously described[21]. Thirty-nine others were selected
because they had recovered from a major depressive epi-
sode (diagnosed according to DSM-III-R criteria), facili-
tated by the capability to respond to standard
antidepressant medication. The response to the antide-
pressant medication was indicated by a score of ≤14 on
the 25 item – Hamilton Depression Rating Scale[22]. The
control group consisted of 85 volunteer students from the
University of Arizona, who denied a personal history of
mental illness based on the mood disorders section of theBehavioral and Brain Functions 2006, 2:24 http://www.behavioralandbrainfunctions.com/content/2/1/24
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Structured Questionnaire Interview for DSM-IV-R (SCID)
questionnaire[23]. All participants were of European
descent.
Genotyping
The study was approved by each of the participating insti-
tutions. All subjects gave written informed consent for
genotyping; samples for DNA analysis were obtained
from whole blood or cheek cells. PCR-based genotyping
was performed at the Laboratory of Molecular Psychiatry
of The University of Arizona for 21 genetic polymor-
phisms. The details of the analyzed polymorphisms can
be found in Table 2. Primer sequences, methodology
details and allele description can be found in TABLE 1S
provided as supplemental information (See additional
file 1). Genotypic frequencies did not deviate from
expected Hardy-Weinberg frequencies.
Statistical analysis
Initially, four comparisons were made: between subjects
with a history of major depression vs. controls, non-
responders vs. controls, responders vs. controls, and non-
responders vs. responders. The data presented in this
study is a result of a chi-square analysis was used to test for
differences in the frequency of genotype polymorphisms
between the depressive subjects and healthy controls as
well as between the responders and non-responders. The
remaining two comparisons (responders vs. controls,
non-responders vs. controls) is available upon request. All
significance tests (aside from QVALUE) were done with
SPSS version 14. Genotypic frequency differences were
analyzed by Chi-Square tests. False discovery rate analysis
was used to control for multiple comparisons between
groups and number of polymorphisms. The q-values[24]
are reported with all p values ≤0.05. A q-value is an indi-
cation of the percent of time a Type I error would be com-
mitted if a corresponding p-value was considered as
statistically significant. For example, we accepted a false
discovery rate of 15%, thus based on the value distribu-
tion of the present dataset, a value of q ≤0.137 was consid-
ered statistically significant, however, this still implies that
13.7% of the time when we accept a corresponding p-
value as statistically significant, an error would be made.
The statistical testing for each polymorphism was between
a risk genotype determined a priori to testing (see Table 2),
and the remaining genotypic groups. The mean number
of risk genotypes among the phenotypic groups was ana-
lyzed using independent samples t-tests. We chose this
approach because we had hypotheses that the history pos-
itive group would have more risk genotypes that the his-
tory negative, and likewise, that the non-responders
would have more risk genotypes that the non-responders.
Results
Table 3 provides the p-value, and corresponding Q-value,
for all the polymorphisms tested. A multiple comparison
correction (Q-value) was used to decrease the number of
false discoveries in the analysis. Genotype frequency dif-
ferences were statistically significant for the serotonin
transporter gene intron-2 VNTR (STin2) between subjects
with a history of depression and controls (p = 0.004). The
disparate genotypic distribution exists in the heterozygote
and 12-repeat homozygote groups. Over 50% of the con-
trols fall into the 12/12 genotypic group, whereas just less
than 30% of the depressed individuals do. Likewise, over
half of the depressed subjects fall in the heterozygote
group, whereas just over 30% of the controls do. The com-
parison between the depressed and non-depressed sub-
jects also revealed that the DRD3  and two COMT
polymorphisms were close to being statistically signifi-
cant but did not hold up to multiple comparison correc-
tion. A statistically significant difference was detected in
the genotypic frequency distributions between the non-
responders and the responders of the DRD4 exon 3 VNTR
(p = 0.009). The genotypic group with zero-7-repeat alle-
les was largely over-represented in the non-responders,
compared to 38% of the responders. Likewise, the
homozygous 7-repeat genotypic group had twice the
amount of responders compared to non-responders.
Figure 1 shows the distribution of the number of risk gen-
otypes for all phenotypic groups. The mean number of
risk genotypes (see Figure 1) is statistically significantly
different between the controls and depressed subjects (p =
Table 1: Clinical description and demographics of subjects groups
Subject term Descriptive clinical information N % female Mean years of age (range)




Clinical diagnosis of chronic or recurrent depression and failure to 
achieve remission after at least two adequate antidepressant trials as 
documented by the Antidepressant Treatment History Form (ATHF).
58 61% 47.2 (24–65)
Responders Clinical diagnosis of major depressive disorder, and capability to 
respond to standard antidepressant medication.
39 75% 46.1 (25–72)
Controls Subjects who denied a personal history of mental illness based on the 
mood disorders section of the Structured Questionnaire Interview for 
DSM-IV-R (SCID) questionnaire.
85 64.3% 23.1 (18–68)Behavioral and Brain Functions 2006, 2:24 http://www.behavioralandbrainfunctions.com/content/2/1/24
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Table 2: Polymorphism Descriptions




location in gene; details
TFAP2B ss/sl transcription factor (CAAA)5–6 6p12–p21.1 intron 2 near 3' splice site of exon 2; 
SLC6A4, HTR2A, DbH, DRD1, SLC6A3 
have Ap2B binding sites
BDNF AA Neurotrophic factor G-->A SNP at 
nucleotide 196; 
rs6265;
11p13 proBDNF coding region; (val66met)
SLC6A4_IN/DEL ll Serotonin transporter 44 bp in/del (5-
HTTLPR)
17q11.1–q12 Promoter; actually a VNTR (xs-xl)
SLC6A4_VNTR 10/12 Serotonin transporter VNTR of 17 bp 
element (9–12 copies)
17q11.1–q12 intron 2
DRD4_IN/DEL sl/ss Dopamine receptor 
D4
120 bp in/del 11p15.5 5'-UTR
DRD4_VNTR 0 or 1 7R Dopamine receptor 
D4
48 bp VNTR 11p15.5 exon 3
HTR2A CC/CT Serotonin post-
synaptic receptor 2A
C102T SNP; rs6313 13q14–q21 exon 1
SLC6A3 9/9 and 9/10 Dopamine 
transporter (SLC6A3)
40 bp VNTR (9 and 10 
repeats most 
frequent, but 3–11 
copies possible)
5p15.3 3' non-coding region of exon 15
rs165599 COMT GG CATECHOL-O-
METHYLTRANSFERA
SE
G-->A SNP (MspI); 
rs165599
22q11.2 3'-UTR; maybe in mRNA
DRD3 GG Dopamine receptor 
D3
G-->A SNP (Glycine--
> serine) (MscI, 
isoschizomer of BalI) 
rs6280
3q13.3 exon 1 (N-terminal extracellular 
domain)
DRD1 GG Dopamine Recptor 
D1
G-->C SNP (HaeIII) 5q35.1 -1251





DRD1 TT Dopamine Recptor 
D1
T-->C SNP (HaeIII) 5q35.1 -800
HTR6 CC Serotonin receptor 
6A
T267C SNP (RsaI) 
Tyr(89) silent 
mutation; rs1805054
1p36–p35 coding region (1st extracellular loop)
DRD1 GG Dopamine Recptor 
D1
G-->A SNP (DdeI) 5q35.1 -48






22q11.2 4th exon (codon 158 or 108)
MAOA ≥3.6R combinations Monoamine Oxidase 
type A
30 bp VNTR (2R, 3R, 
3.6R, 4R, 5R, 7R)
Xp11.23 1.2 kb upstream of coding region; 
promoter
HTR1A GG/CG Serotonin Receptor 
1A
C-->G SNP (BstF5I) at 
position -1019 from 
ATG start site
5q11.2–q13 PCR fragment is from -1158 to -996 
from ATG start site strobel, 2003; 
promoter
DBH TT (A1/A1) Dopamine-beta-
hydroxylase
C-->T SNp at position 
1604; R535C (BstUI); 
rs6271
9q34 exon 11: 142 bp fragment (originally 
FnuDII digest). A1: 95, 47 bp; A2: 66, 47, 
29 bp.
TPH2 GG Tryptophan 
Hydroxylase 2 
(neuronal TPH)
A-->G; rs1386494 12q21.1 intron 5
TH 0,1 Tyrosine Hydroxylase VNTR 11p15.5Behavioral and Brain Functions 2006, 2:24 http://www.behavioralandbrainfunctions.com/content/2/1/24
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0.017) as well as between controls and non-responders (p
= 0.005).
Discussion
The genetic susceptibility to major depression was tested
using genotype frequency comparisons between subjects
with a history of depression and controls. We detected
three polymorphisms (SLC6A4 intron 2 VNTR, 2 COMT
polymorphisms) which may contribute to the genetic sus-
ceptibility to major depression, however, only one
(SLC6A4) which held up to multiple comparison correc-
tions.
The comparison between the non-responders and
responders is a method to detect the genetic basis for anti-
depressant response, in general. Out of the 21 polymor-
phisms tested, only one (DRD4  exon 3 VNTR) was
statistically significant. This is compared to the 3–4 poly-
morphisms which demonstrate a genetic susceptibility to
depression. It was unpredicted that the genetic basis for
antidepressant response may differ from the genetic basis
of susceptibility to major depression.
We further demonstrated that the number of risk geno-
types is not consistent across phenotypes. The non-
responders have the most risk genotypes, followed by (in
decreasing order) the depressed group as a whole, the
responders, and the controls. This supports the notion
that Major Depressive Disorder is polygenic, and that the
number of risk genotypes may be an indication of the sus-
ceptibility to Major Depressive Disorder as well as the
severity of the disorder.
In retrospect, we recognize that much of our current
understanding of the pathophysiology of depressive dis-
orders has been inferred from the prevailing hypotheses
of mechanisms for antidepressant action. Accordingly,
candidate genes selected for their function are commonly
associated with monoamine function or their putative
intracellular responses to neurotransmitter activation. The
neurobiology of treatment resistance is not well under-
stood; it may represent an extreme phenotype along a
unique pathological continuum of depression. This inter-
pretation may be supported by the fact that the usual
monoamine-based treatment interventions, by definition,
provide little or no benefit to patients with treatment
resistant depression.
The Hamilton Depression Rating Scale has been for dec-
ades the gold standard of depression symptoms quantifi-
cation and has been utilized in >95% of antidepressant
treatment studies. There have been lately a number of
concerns primarily about the scale's ability to reliably
quantify antidepressant responses given the multi-dimen-
sionality of the scale, which may non-specifically deter-
mine response in individuals treated with sedating agents
such as TCA's. In the other hand, given the number of
non-melancholic specific items, it may be less sensitive at
detecting an antidepressant response. It is possible that
alternative tools such as the Bech Rafelsen or the Mont-
gomery Asberg Depression Rating Scale among others
may more accurately reflect antidepressant responses
leading to a more reliable detection of therapeutic effects.
This pilot study provides a proof of concept that two
depressive phenotypes (antidepressant response and non-
response) may be subtypes of Major Depressive Disorder.
In terms of medication response, these patients are clearly
Distribution of risk genotypes for all phenotypic groups  (mean # risk genotypes ± SEM) Figure 1
Distribution of risk genotypes for all phenotypic groups 
(mean # risk genotypes ± SEM).
Table 3: P and Q-values for trending and statistically significant (after multiple comparison correction *) polymorphisms
Depressed vs. non-depressed Responders vs. non-responders
Polymorphism p-value q-value p-value q-value
rs6280 DRD3 0.055 0.264 0.439 0.555
rs4680 COMT 0.033 0.239 0.986 0.77
rs165599 COMT 0.041 0.239 0.251 0.482
STin2 VNTR SLC6A4 0.004* 0.137 0.749 0.699
exon 3 VNTR DRD4 0.316 0.482 0.009* 0.137Behavioral and Brain Functions 2006, 2:24 http://www.behavioralandbrainfunctions.com/content/2/1/24
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distinct from each other, thus it is logical to propose their
genetic constitution may be distinct. The polymorphisms
analyzed in this study is by no means an exhaustive list of
polymorphisms which play a role in Major Depressive
Disorder, however it is a fairly representative list for the
monoamine related polymorphisms thought to confer
susceptibility to major depression. It is true that the mean
age of the controls is younger compared to the depressed
groups, thus they have not necessarily passed the age of
onset typical of major depressive disorder. As a result, we
may be committing a type I error in the analyses, and be
missing or underestimating genetic differences that exist
between the controls and depressed subjects, however, we
are confident in the effect that we did detect. A large
number of comparisons between groups for each poly-
morphism were initially performed in this study. To cor-
rect for false discovery, a q-value was determined, which
provided an indication of statistical significance. We
accepted a q-value less than 15%, which indicates that
15% of the time we considered out findings to be signifi-
cant, we would be incorrect. Given that this is a pilot study
with relatively small sample size, our single-polymor-
phism findings may be false positives, and thus necessi-
tate replication in an independent and larger sample.
Polymorphisms in alternative neurotransmitter systems,
neurotrophic pathways, neurosteroids and antidepressant
metabolic pathways (e.g. cytochrome p450 factors)
should be the focus of further research.
Conclusion
Despite the modest sample size, these data support the
existence of a genetic basis to the susceptibility to major
depression. Furthermore, depending on the phenotypic
definition used in testing, different associations may be
detected. Given that we utilized phenotypic definitions
based on patters of treatment response, these findings fur-
ther suggest that the genetic basis for the capacity to
respond to monoamine-based antidepressants is different
from that of susceptibility to major depression. These data
provide a proof of concept that major depressive disorder
Table 4: Genotype frequencies for polymorphisms in Table 3 for all phenotypic groups. Risk genotype indiciated by an *.
rs6280 DRD3 AA AG GG*
controls 46 (.55) 34 (.41) 3 (.04)
depressed 47 (.50) 34 (.36) 14 (.14)
responder 18 (.47) 12 (.32) 8 (.21)
non-responder 29 (.51) 22 (.39) 6 (.10)
rs4680 COMT AA AG GG*
controls 26 (.31) 43 (.52) 14 (.17)
depressed 30 (.32) 34 (.36) 30 (.32)
responder 12 (.32) 13 (.35) 12 (.32)
non-responder 18 (.31) 21 (.37) 18 (.31)
rs165599 COMT AA AG GG*
controls 46 (.56) 30 (.37) 6 (.07)
depressed 40 (.43) 34 (.37) 18 (.20)
responder 13 (.35) 14 (.38) 10 (.27)
non-responder 27 (.49) 20 (.36) 8 (.15)
STin2 VNTR SLC6A4 10/10 10/12* 12/12
controls 15 (.18) 25 (.31) 42 (.51)
depressed 18 (.19) 49 (.52) 27 (.29)
responder 8 (.21) 18 (.47) 12 (.32)
non-responder 10 (.18) 31 (.55) 15 (.27)
Exon 3 VNTR DRD4 0–7R* 1–7R* 2–7R
controls 56 (67) 22 (.26) 6 (.07)
depressed 55 (.57) 36 (.38) 5 (.05)
responder 15 (.38) 21 (.54) 3 (.08)
non-responder 40 (.70) 15 (.26) 2 (.04)Behavioral and Brain Functions 2006, 2:24 http://www.behavioralandbrainfunctions.com/content/2/1/24
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is a polygenic disorder, and that the number of risk geno-
types may be an indication of susceptibility to the disor-
der and the severity.
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